1.17
-0.16(-12.03%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.33 |
| Day High | 1.36 |
| Day Low | 1.07 |
| 52-Week High | 3.4 |
| 52-Week Low | 1.07 |
| Volume | 675,971 |
| Average Volume | 139,151 |
| Market Cap | 31.74M |
| PE | -2.17 |
| EPS | -0.54 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 1.74 |
| Change | -0.16 |
If you invested $1000 in Ocuphire Pharma, Inc. (OCUP) 10 years ago, it would be worth $3.34 as of March 13, 2025 at a share price of $1.17. Whereas If you bought $1000 worth of Ocuphire Pharma, Inc. (OCUP) shares 5 years ago, it would be worth $179.45 as of March 13, 2025 at a share price of $1.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Ocuphire Pharma Announces Acquisition of Opus Genetics
GlobeNewswire Inc.
Oct 22, 2024 8:05 PM GMT
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal
Ocuphire Pharma Announces Acquisition of Opus Genetics
GlobeNewswire Inc.
Oct 22, 2024 8:05 PM GMT
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
GlobeNewswire Inc.
Sep 30, 2024 12:00 PM GMT
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profileFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clin